Adial Pharmaceuticals Inc's Comment on Sales, Marketing and Customers
The text addresses the use of ondansetron doses for treating Alcohol Use Disorder (AUD). It notes that Zofran® tablets, currently approved for nausea and emesis, are not appropriate substitutes for the AD04 dose required for AUD treatment due to differences in dosing and safety profiles. High doses of ondansetron have not demonstrated efficacy in clinical trials for AUD and may present significant cardiovascular risks, leading to reluctance among physicians to prescribe them. The FDA has withdrawn approval for a high-dose Zofran® product and issued warnings regarding potential heart rhythm risks at marketed doses. In contrast, AD04 employs a lower ondansetron dose that the FDA has approved for chronic use without additional safety studies, positioning it as a safer option for AUD treatment. The primary market segment includes patients with addictions such as AUD, with prescribing physicians as the customers. The FDA and Zofran® are the regulatory and product entities referenced.
Adial Pharmaceuticals Advances Precision Medicine Approach for Alcohol Use Disorder with Promising Developments in AD04 Clinical Trials and ResearchAdial Pharmaceuticals is making significant strides in the field of precision medicine for the treatment of Alcohol Use Disorder (AUD) with its flagship investigational drug, AD04. The company recently announced several key milestones that underscore the potential efficacy and imminent progression of AD04 through its clinical pipeline. Database Lock Achieved in AD04 Pharmacokinetics StudyOne of the most critical recent developments comes from Adial Pharmaceuticals announcement of a database lock in their pharmacokinetics study of AD04. This crucial step indicat...
GLEN ALLEN, Va. Sept. 04, 2024 Adial Pharmaceuticals, Inc. (NASDAQ: ADIL), a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for the treatment and prevention of addiction and related disorders, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled to take place from September 9 to 11, 2024, at the Lotte New York Palace Hotel in New York City.Cary Claiborne, the CEO of Adial Pharmaceuticals, will represent the company at this prestigious conference. Claiborne will discuss the company’s recent milestones, ongoing clinical trials, and future plans. This presentation is a critical opportunity for Adial to...
Precision Medicine for Alcohol Use Disorder: Promising Efficacy of AD04 : Recent findings suggest that AD04, a potential precision medicine targeting Alcohol Use Disorder (AUD), significantly reduces heavy drinking days in patients with a specific genetic profile. This publication in a leading peer-reviewed journal posits that AD04, coupled with a companion diagnostic test (CDx), may offer a novel and effective treatment approach. The impact on Adial Pharmaceuticals Inc. is profound, poised to transform both clinical and financial landscapes. Alcohol Use Disorder (AUD) is a chronic and often debilitating condition characterized by an inability to control or stop alcohol consumption despite adverse consequ...
Adial Pharmaceuticals Inc’s Comment on Sales, Marketing and Customers
The text addresses the use of ondansetron doses for treating Alcohol Use Disorder (AUD). It notes that Zofran® tablets, currently approved for nausea and emesis, are not appropriate substitutes for the AD04 dose required for AUD treatment due to differences in dosing and safety profiles. High doses of ondansetron have not demonstrated efficacy in clinical trials for AUD and may present significant cardiovascular risks, leading to reluctance among physicians to prescribe them. The FDA has withdrawn approval for a high-dose Zofran® product and issued warnings regarding potential heart rhythm risks at marketed doses. In contrast, AD04 employs a lower ondansetron dose that the FDA has approved for chronic use without additional safety studies, positioning it as a safer option for AUD treatment. The primary market segment includes patients with addictions such as AUD, with prescribing physicians as the customers. The FDA and Zofran® are the regulatory and product entities referenced.
Sources:
Adial Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Adial Pharmaceuticals Inc’s corporate clients.
For your research, we’ve provided 9 tables on Adial Pharmaceuticals Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
